Bio-Path Holdings, Inc. (BPTH)

Market Cap	3.01M
Revenue (ttm)	n/a
Net Income (ttm)	-11.60M
Shares Out	3.71M
EPS (ttm)	-13.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,651
Open	0.970
Previous Close	0.900
Day's Range	0.813 - 0.970
52-Week Range	0.800 - 12.400
Beta	0.22
Analysts	Strong Buy
Price Target	30.00 (+3,592.31%)
Earnings Date	Nov 15, 2024

About BPTH

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also de...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: BPTH
• Website: https://www.biopathholdings.com

Analyst Forecast

According to 2 analysts, the average rating for BPTH stock is "Strong Buy." The 12-month stock price forecast is $30.0, which is an increase of 3,592.31% from the latest price.

Price Target

$30.0

(3,592.31% upside)

Analyst Consensus: Strong Buy